Skip Navigation LinksHome > January 2003 - Volume 98 - Issue 1 > Halogenated Anesthetics Reduce Interleukin-1β-induced Cytoki...
Laboratory Investigations

Halogenated Anesthetics Reduce Interleukin-1β-induced Cytokine Secretion by Rat Alveolar Type II Cells in Primary Culture

Giraud, Olivier M.D.*; Molliex, Serge M.D., Ph.D.†; Rolland, Corinne B.Sc.‡; Leçon-Malas, Véronique B.Sc.§; Desmonts, Jean-Marie M.D.∥; Aubier, Michel M.D., Ph.D.#; Dehoux, Monique Ph.D.**

Free Access
Article Outline
Collapse Box

Author Information

Collapse Box


Background: Alveolar epithelial type II (ATII) cells participate in the intraalveolar cytokine network by secreting cytokines and are widely exposed to volatile anesthetics during general anesthesia. The aim of the current study was to evaluate the effects of halothane, enflurane, and isoflurane on rat ATII cell cytokine secretions in ATII primary cell cultures.
Methods: Alveolar epithelial type II primary cell cultures were obtained from adult rat lungs. ATII cells were stimulated by recombinant murine interleukin-1β (rmIL-1β) to mimic an inflammatory response, and immediately exposed for various duration to different concentration of halothane, enflurane, or isoflurane. Interleukin-6, macrophage inflammatory protein-2 (MIP-2), and monocyte chemoattractant protein-1 (MCP-1) protein concentrations were then measured in cell culture supernatants. Recombinant mIL-1β-stimulated ATII cells exposed to air served as control.
Results: Halothane, isoflurane, and enflurane (1 minimum alveolar concentration [MAC], 4 h) decreased rmIL-1β-stimulated ATII cell secretions of interleukin-6, MIP-2, and MCP-1, but did not modify total protein secretion. Halothane exposure decreased rmIL-1β-stimulated ATII cell secretions of interleukin-6, MIP-2, and MCP-1 in a dose- and time-dependent manner. Total protein concentrations remained unchanged except at 1.5 MAC of halothane, and no cytotoxic effect could be evidenced by lactate dehydrogenase release. These effects were transient as rmIL-1β-stimulated ATII cell secretions of interleukin-6 and MIP-2 progressively reached control values between 4 and 24 h after the end of halothane exposure. However, MCP-1 inhibition persisted until 24 h. rmIL-1β-induced MIP-2 and tumor necrosis factor-α mRNA expression were decreased by 36 and 24%, respectively, after halothane exposure.
Conclusions: The current study shows that exposure of rmIL-1β-stimulated ATII cells to volatile anesthetics reversibly alters their cytokine secretion. Therefore, volatile anesthesia, by modulating pulmonary epithelial cell secretion of inflammatory cytokines, might affect the lung inflammatory response.
ALVEOLAR epithelial type II cells (ATII) play an important role in the alveolar space. ATII cells synthesize and secrete surfactant, regulate the epithelial fluid clearance, and proliferate and differentiate into alveolar type I cells, particularly in case of epithelial injury. 1 Moreover, ATII cells participate with alveolar inflammatory cells, to the intraalveolar cytokine network, by secreting interleukin-6, 2 macrophage inflammatory protein-2 (MIP-2), a murine analog of interleukin-8, 3 cytokine-induced neutrophil chemoattractant, 4 monocyte chemoattractant protein-1 (MCP-1), 5 and tumor necrosis factor-α (TNF-α). 6,7In vitro, unstimulated ATII cells secrete low amounts of cytokines. However, several studies have documented a potent cytokine secretion by ATII cells either in vivo, in response to lung injury, or in vitro, in response to interleukin-1β stimulation. 3-5,8–10 It has been also shown that ATII cells secrete low amounts of TNF-α after lipopolysaccharide stimulation 6 and that TNF-α induces MIP-2 production by alveolar epithelial cells. 7
Alveolar epithelial type II cells are exposed to volatile anesthetic agents throughout the duration of anesthesia, as these agents are delivered to and principally eliminated by the lungs. However, little is known regarding the effects of volatile anesthetics on pulmonary cell functions. Halothane and other volatile anesthetics are known to modify cellular metabolism. 11,12 Indeed, it has been demonstrated that elevated concentrations of halothane have an inhibitory effect on protein synthesis in perfused rat lung. 13–15 Volatile anesthetics can also modulate the immune response by decreasing neutrophil functions in vitro16–18 and cytokine release by human peripheral blood mononuclear cells. 19In vitro studies from our laboratory also showed that halothane inhibits surfactant phospholipids and apoprotein biosynthesis by rat ATII cells 20,21 and decreases Na-K-ATPase and sodium channel activities. 22
Little is known about the effects of volatile anesthetics on lung inflammatory response. In a previous in vivo study, we have shown that halothane reduces the lung inflammatory response induced by intratracheal lipopolysaccharide instillation in mechanically ventilated rats. 23 Indeed, 1% halothane delivered during 4 h through mechanical ventilation decreased the lipopolysaccharide-induced recruitment of neutrophils and secretion of TNF-α, interleukin-6, and MIP-2 in the bronchoalveolar fluid. MIP-2 and TNF-α mRNA expression in lung homogenates was also decreased. Several cellular sources of cytokines within the lung, including inflammatory cells and ATII cells, might have been affected by halothane exposure. As yet the effects of halothane on cytokine secretion by ATII cells remain unknown.
As ATII cells, under various conditions, are a potent source of cytokines within the lungs as well as a potential target for volatile anesthetics, the aim of the current work was to evaluate the effects of halothane, enflurane, and isoflurane on cytokine secretions by rat ATII primary cell culture. As in our previous in vivo study, the effects of halothane were only observed during a lung inflammatory process; recombinant murine interleukin-1β (rmIL-1β) was used to stimulate ATII cells and to mimic an inflammatory setting.
Back to Top | Article Outline

Materials and Methods

This study, including care of the animals involved, was conducted according to the official edict presented by the French Ministry of Agriculture (Paris, France) and the recommendations of the Helsinski Declaration. Thus, these experiments were conducted in an authorized laboratory and under the supervision of authorized researchers.
Back to Top | Article Outline
Isolation of Rat Alveolar Type II Cells
Alveolar type II cells were isolated from adult rat lungs by enzymatic dissociation and purified by differential adherence to plastic as previously describe. 24 Cells (3 × 106) were plated in a 60-mm-diameter cell culture dish (Costar Corp., Cambridge, MA) with 2 ml of Dulbecco's modified Eagle medium (DMEM; Gibco Life Technologies, Cergy-Pontoise, France) containing 15% fetal bovine serum (Gibco Life Technologies), 105 IU/ml penicillin, 100 μg/ml streptomycin, and 250 ng/ml amphotericin B (complete DMEM). The dishes were incubated 24 h at 37°C with a 95% air-5% CO2 mixture. The incubator atmosphere was continuously kept saturated with water.
After a 24-h period, nonadherent cells were removed by gently washing twice with phosphate-buffered saline. Subsequently, 2 ml fresh complete DMEM was added and the cells were used for the experiments. ATII cells were identified by the modified Papanicolaou stain and by phosphine fluorescence staining. 25 A total of 93 ± 2% (mean ± SEM, n = 12) of adherent cells were ATII cells 24 h after rat lung isolation. Adherent cell viability was higher than 98% as assessed by the trypan blue exclusion test.
Back to Top | Article Outline
Volatile Anesthetic Exposure and Experimental Design
Alveolar type II cells were stimulated with 1 ng/ml rmIL-1β (R&D Systems, Abingdon, UK) to induce their cytokine secretion and to mimic an inflammatory response.They were then exposed to either air or volatile anesthetics as previously described. 20,21 ATII cells were incubated in a 12-l air-tight Lwolff chamber at 37°C and 5% CO2. The chamber atmosphere was continuously kept saturated with water. Volatile anesthetic vapors were provided into the chamber by directing a 95% air-5% CO2 mixture through volatile anesthetic vaporizers placed on the entrance of the chamber. A volatile anesthetic monitor (Capnomac; Datex, Helsinki, Finland) determined the concentration of the anesthetic agents exiting the chamber. The chambers were sealed when the desired concentration was obtained.
To analyze the effects of different volatile anesthetics on cytokine secretion, rmIL-1β-stimulated ATII cells were incubated during 4 h at 37°C with 1 minimum alveolar concentration (MAC) of halothane (1%), isoflurane (1.5%), or enflurane (2.2%), i.e., clinically relevant concentration. 26 Control cells were rmIL-1β-stimulated ATII cells only exposed to a water-saturated 95% air-5% CO2 mixture during 4 h. Each experimental condition was performed in duplicate.
To study a dose-response effect, rmIL-1β-stimulated ATII cells were exposed to volatile anesthetic vapors provided into the chamber by directing a 95% air-5% CO2 mixture through volatile anesthetic vaporizers placed on the entrance of the chamber for 4 h to 0, 0.5, 1, and 1.5% of halothane.
To determine a relation between duration of exposure to halothane and ATII cell cytokine secretion, rmIL-1β-stimulated ATII cells were exposed to volatile anesthetic vapors provided into the chamber by directing a 95% air-5% CO2 mixture through volatile anesthetic vaporizers placed on the entrance of the chamber in the presence or absence of 1% halothane for 1, 2, 3, and 4 h as described above.
Finally, to determine the reversibility of halothane exposure (4 h, 1%), rmIL-1β-stimulated ATII cells were maintained incubated in the same culture medium at 37°C with a 95% air-5% CO2 mixture (without halothane) for 1, 2, 4, and 24 h following halothane or air exposure. The incubator atmosphere was kept continuously saturated with water.
At the end of the culture period or volatile anesthetic exposure, supernatants from duplicate cell cultures were collected and immediately frozen at −20°C to measure the concentration of interleukin-6, MIP-2, MCP-1, total proteins, and lactate dehydrogenase (LDH) activities. Total cellular mRNA from ATII adherent cells (3 × 106 ATII) were extracted using 2 ml of Trizol (Gibco) following the manufacturer's instructions.
Back to Top | Article Outline
Protein Assay
Total protein content in cell supernatants was measured with a pyrogallol-red-molybdate complex 27 on an automatic Hitachi-911 analyzer (Boehringer-Mannheim, Paris, France).
Back to Top | Article Outline
Interleukin-6 Assay
Bioactive interleukin-6 was measured in cell supernatants using the interleukin-6-dependent B9 hybridoma cell line. 28 B9 cells were cultured for 72 h in presence of duplicate serial dilutions of the specimens in 96-well plates. B9 cell proliferation was estimated after 72 h of incubation at 37°C in 5% CO2 using MTT colorimetric assay. 29 Human recombinant interleukin-6 was used as an internal standard in all assays. One unit of interleukin-6 was defined by the half-maximal proliferation of B9 cells.
Back to Top | Article Outline
Macrophage Inflammatory Protein-2 and Monocyte Chemoattractant Protein-1 Assays
The amount of MIP-2 and MCP-1 in cell supernatants was determined with commercially available enzyme-linked immunosorbent assay kits (Cytoscreen MIP-2/MCP-1; Biosource, Montrouge, France), following the manufacturer's instruction. The detection limit was 1 pg/ml and 8 pg/ml for MIP-2 and MCP-1, respectively.
Back to Top | Article Outline
Reverse-transcriptase Polymerase Chain Reaction
After extraction, total cell RNA was submitted to a reverse transcription. Four microliters of total RNA (0.5 μg/μl) in presence of 3 μl of oligo-dT (0.8 μg/μl; Promega, Charbonnieres, France) was heated to 70°C for 5 min in a thermocycler (Gene Amp; Perkin Helmer, Norwalk, CT). Then, at 4°C, 2.5 μl of deoxyribonucleoside triphosphate (10 mm; Boerhinger-Mannheim, Mannheim, Germany) and 2 μl of avian myeloblastosis virus reverse transcriptase (32 IU/μl; Boerhinger-Mannheim) were added to a final volume of 25 μl in RNAse-free water. The reverse transcription was performed in a thermocycler that heated to 42°C for 45 min and to 99°C for 5 min. The final cDNA products were stored at −20°C.
Back to Top | Article Outline
Polymerase Chain Reaction for Macrophage Inflammatory Protein-2 and Tumor Necrosis Factor-α
Polymerase chain reaction for MIP-2 and TNF-α was performed by mixing 2 μl cDNA, 12.5 μl deoxyribonucleoside triphosphate (1 mm; Boerhinger-Mannheim), 5 μl MgCl2 (50 mm; Gibco), 2 μl sense primer (12 μm, MIP-2 = 5′-GGC ACA ATC GGT ACG ATC CAG-3′ or TNF-α = 5′-GCC ACC ACG CTC TTC TGT CT-3′), 2 μl antisense primer (12 μm, MIP-2 = 5′-ACC CTG CCA AGG GTT GAC TTC-3′ or TNF-α = 5′-GGG CTA CGG GCT TGT CAC T-3′), 2 μl sense primer S14 (12 μm, 5′-ATC AAA CTC CGG GCC ACA GGA-3′), 2 μl antisense primer of S14 (5′-GTG CTG TCA GAG GGG ATG GGG-3′) to a final volume of 48 μl in Rnase-free water. This mixture was heated at 80°C for 5 min, then 2 μl of Taq polymerase (1.25 μg/μl; Gibco) was added. Twenty-five repeated cycles of heat denaturation (94°C for 30 s), annealing of the primers (59°C for 30 s), and extension of the annealed primers (72°C for 30 s) were performed.
Macrophage inflammatory protein-2, TNF-α, and S14 cDNA were size fractionated by electrophoresis through a 3% agarose gel containing 2% of Tris-buffer saline (1 mm; Sigma, Saint-Quentin Falavier, France) and 0.01% of Vista Green nucleic acid gel stain (Amersham Life Science, Orsay, France). The intensity of each band was measured under ultraviolet light with a charge-coupled device camera using image analyzer (Gel Analyst; Iconix, Santa Monica, CA). The size of MIP-2, TNF-α, and S14 amplification products were, respectively, 287, 151, and 134 base pairs. MIP-2 mRNA was expressed as the percentage of the housekeeping gene S14 mRNA. This technique permitted semiquantitative analysis of the reverse-transcription polymerase chain reaction.
Back to Top | Article Outline
Lactate Dehydrogenase Assay
To determine whether halothane exposure had cytotoxic effect on ATII cells, LDH activity was measured in the ATII cell supernatants 30 with an automatic Hitachi-911 analyzer (Boehringer-Mannheim, Paris, France) and expressed as international units per milliliter.
Back to Top | Article Outline
Statistical Analysis
All results are expressed as the percentage of values obtained for air-exposed cells (mean ± SD) derived from at least n = 3 independent experiments, each conducted in duplicate. The statistical analysis was performed with the program Sigma Stat (Jandel Scientific, San Jose, CA). Between-group differences were first assessed with the Kruskall-Wallis test and then, in the case of global significant difference, individual group means were compared with a nonparametric Mann-Whitney U test. A P value < 0.05 was considered significant.
Back to Top | Article Outline


Effects of Halothane, Isoflurane, and Enflurane on Cytokine and Protein Productions by Recombinant Murine Interleukin-1β-stimulated Alveolar Epithelial Type II Cells
Fig. 1
Fig. 1
Image Tools
As expected, rmIL-1β increased the secretion of interleukin-6, MIP-2, MCP-1 (50-, 13-, and 10-fold, respectively;P < 0.001) and total protein concentrations as compared with unstimulated ATII cells (fig. 1).
Fig. 2
Fig. 2
Image Tools
Exposure of rmIL-1β-stimulated ATII cells to 1 MAC of halothane, isoflurane, and enflurane during 4 h decreased interleukin-6 concentration by 51 ± 18.5, 53 ± 17.3, and 49 ± 18.9%, respectively (P < 0.001), MIP-2 concentration by 53 ± 18.2, 57 ± 19.5, and 51 ± 17.7%, respectively (P < 0.001), and the MCP-1 concentration by 31 ± 15.2, 33 ± 14.3, and 30 ± 12.2%, respectively (P < 0.05), while total protein secretion was not changed (fig. 2). No difference was observed between the effects of halothane, isoflurane, and enflurane. Thus, all further experiments were only performed with halothane.
Back to Top | Article Outline
Dose-dependent Effect of Halothane on Cytokine Production
Fig. 3
Fig. 3
Image Tools
The exposure of rmIL-1β-stimulated ATII cells during 4 h at increasing concentrations of halothane (i.e., 0.5, 1, and 1.5 MAC) decreased interleukin-6 concentration by 22 ± 12.2, 61 ± 15, and 69 ± 16.6%, respectively (P < 0.05), MIP-2 concentration by 24 ± 16.4, 52 ± 17.4, and 64 ± 16.9%, respectively (P < 0.05), and MCP-1 concentration by 21 ± 12.8, 22 ± 14.1, and 55 ± 15.9%, respectively (P < 0.05). Total protein concentrations were not modified when using 0.5 and 1 MAC of halothane but were significantly decreased (19%;P < 0.05) at 1.5 MAC of halothane (fig. 3).
Fig. 4
Fig. 4
Image Tools
Lactate dehydrogenase activities were measured in cell culture supernatants to rule out a direct cytotoxic effect of halothane. LDH activities were not modified after exposure to 0.5 and 1 MAC of halothane (+1.7 ± 1.4 and +1.2 ± 0.9%, respectively, vs. control; not significant). By contrast, exposure to 1.5 MAC of halothane led to an increased LDH activity (+11.5 ± 3.2%vs. control;P < 0.05;fig. 4).
Back to Top | Article Outline
Time-dependent Effect of Halothane on Cytokine Productions
Fig. 5
Fig. 5
Image Tools
Exposure of rmIL-1β-stimulated ATII cells to halothane at 1 MAC during 1, 2, 3, and 4 h induced a progressive inhibition of cytokine secretion 2 h after the onset of halothane exposure (fig. 5). Indeed, after a 2-h period of halothane exposure, both interleukin-6 and MIP-2 were significantly decreased (P < 0.05) as compared with air-exposed cells. The decrease in MCP-1 concentrations reached significance at the third hour as compared with air-exposed cells. Total protein concentration remained unchanged during all intervals of exposure to halothane.
Back to Top | Article Outline
Reversibility of Halothane Effects
After either air (control) or halothane exposure (1 MAC, 4 h), the ATII cell chamber atmosphere was washed with air, and the ATII cell supernatants were collected 1, 2, 4, and 24 h after the end of halothane exposure.
Fig. 6
Fig. 6
Image Tools
As shown in figure 6, both interleukin-6 and MIP-2 secretions increased progressively after the end of halothane exposure to reach control values between the 4th and 24th hour. As opposed, MCP-1 secretion remained inhibited until the 24th hour after the end of halothane exposure.
Back to Top | Article Outline
Messenger RNA Expression of Macrophage Inflammatory Protein-2 and Tumor Necrosis Factor-α
Fig. 7
Fig. 7
Image Tools
Messenger RNA expression of MIP-2 in unstimulated ATII cells was under the detection limit (fig. 7). rmIL-1β stimulation induced an increase in MIP-2 mRNA in ATII cells (air group). In agreement with MIP-2 protein concentration, MIP-2 mRNA expression was decreased by 36 ± 13.9% (P < 0.001) in ATII cells exposed to 1% halothane for 4 h.
Fig. 8
Fig. 8
Image Tools
Alveolar type II cells are well known to only produce low concentrations of TNF-α, even in the presence of proinflammatory cytokine such as interleukin-1β. Therefore, we did not measure TNF-α protein secretion by ATII cells exposed to volatile anesthetics. However, as TNF-α secreted by ATII cells has been involved in the regulation of MIP-2 synthesis in an autocrine loop, 7 we also investigated the effect of halothane on TNF-α mRNA expression. TNF-α mRNA expression in unstimulated ATII cells was under the detection limit (fig. 8), and rmIL-1β stimulation induced an increase of TNF-α mRNA expression in air-exposed cells. Halothane exposure (1 MAC, 4 h) decreased TNF-α mRNA expression by 24 ± 11.3% as compared with air-exposed rmIL-1β-stimulated ATII cells (P < 0.001).
Back to Top | Article Outline


The main result of our study is that halothane, isoflurane, and enflurane reduced the rmIL-1β-stimulated ATII cell cytokine secretion. Halothane reduced the secretion of interleukin-6, MIP-2, and MCP-1 proteins in a time- and dose-dependent manner, in association with a decrease in MIP-2 and TNF-α mRNA expression. This reduced cytokine secretion was transient and reversible between the 4th and 24th hour after the end of volatile anesthetic exposure.
Most of our findings are in agreement with our previous in vivo study. 23 In the latter, we demonstrated, in mechanically ventilated rats, that 4 h of 1% (1 MAC) halothane exposure decreased the lung inflammatory response induced by intratracheal instillation of lipopolysaccharide. Neutrophil recruitment was reduced and was tightly correlated with MIP-2 secretion in the bronchoalveolar lavage fluid. This was accompanied by a decrease in interleukin-6, TNF-α protein concentrations, and MIP-2 and TNF-α mRNA expression in the bronchoalveolar lavage fluid and lung homogenates. These results observed in vivo might be explained, at least in part, by an inhibitory effect of volatile anesthetics on cytokine secretion by ATII cells. Only a few investigations have documented the effects of volatile anesthetics on cell cytokine secretion, and contradictory effects have been reported. In agreement with our results, Mitsuhata et al.19 have shown that in vitro production of TNF-α and IL-1 by peripheral blood mononuclear cells was inhibited by enflurane, isoflurane, and sevoflurane, the latter compound being the most effective to inhibit cytokine release. In the current study, we did not observe any difference between halothane, enflurane, and isoflurane. By contrast, Kotani et al.31 have found ex vivo, that exposure of rat alveolar macrophages to volatile anesthetics and mechanical ventilation augmented mRNA expression of interleukin-1β, MIP-2, interferon-γ, and TNF-α as compared with mechanical ventilation alone. These increases were associated with a significant increase in MIP-2 and TNF-α protein in the bronchoalveolar lavage fluid from ventilated rats. 31 However, in the latter work, rat alveolar macrophage cytokine expression was studied in basal conditions, without any further stimulation. In our study, the basal concentrations of interleukin-6, MIP-2, and MCP-1 in unstimulated ATII cell supernatants were not modified by the volatile anesthetics.
In contrast to the results found in this in vitro investigation, our previous data obtained in an in vivo model, in which the animals received intratracheal lipopolysaccharide, did not show a significant change in MCP-1 concentration after exposure to halothane. 23 A possible explanation for these discordant results is that bronchoalveolar lavage fluid represents the cytokine secretion of the overall cells, including at least ATII cells, alveolar macrophages, and neutrophils. These rat lung cells might have their cytokine secretions differentially altered by halothane, and the decrease of in vitro ATII cell MCP-1 secretion by halothane might be blinded in vivo by the secretion of MCP-1 originating from other cells such as alveolar macrophages. Indeed, alveolar macrophages represented the most important producer of inflammatory cytokines, 32 and their cytokine secretions might be differently affected by halothane exposure.
The mechanisms by which ATII cell cytokine secretion was decreased remain to be determined. As total protein concentration in cell supernatants was not modified until 1.5% of halothane, the decreased inflammatory cytokine secretion could not be caused by an inhibition of global protein secretion. These results are in agreement with two previous studies that showed that halothane decreased the protein synthesis for halothane concentrations higher than 2% and for time exposure longer than 6 h. 14,15 A cytotoxic effect can also be excluded as LDH activity remained unchanged even after 4 h of 1% halothane exposure. These findings are in agreement with the study of Molliex et al., 20 who demonstrated a cytotoxic effect of halothane only for long exposure periods, i.e., 8 and 12 h, and for elevated halothane concentrations, i.e., 8%.
We showed that MIP-2 and TNF-α steady state mRNA concentrations were decreased in ATII cells. Since halothane was able to decrease mRNA concentration, 33 halothane might have directly decreased MIP-2 and TNF-α secretion by acting, at least in part, at the transcriptional level. The decrease of MIP-2 protein in ATII cell supernatants might have been indirectly induced by the decreased in TNF-α, which is able to induce MIP-2 secretion. 7
Recently, Tschaikowsky et al.34 have shown that the expression of inducible nitric oxide synthase by immunostimulated murine macrophage-like cell line was affected by volatile anesthetics through intracellular calcium changes. In this connection, volatile anesthetics have been shown to reversibly inhibit voltage-dependent calcium channels and affect intracellular calcium mobilization, resulting in a decreased concentration of intracellular Ca2+. 17,35,36
Whatever the mechanism involved, it is noteworthy that the effect of volatile anesthetic on ATII cytokine secretion was transient. Indeed, we showed that the inhibitory effect of volatile anesthetic was rapidly reversible after the end of exposure. These findings are in agreement with our in vivo study and suggest that, in clinical practice, the inhibitory effect of volatile anesthetic might be limited to the operative or early postoperative period. It remains, however, to determine the effects of volatile anesthetics in clinical practice, particularly in the genesis of lung infection in the postsurgical period.
In conclusion, our study demonstrates that rmIL-1β-stimulated ATII exposure to volatile anesthetics reversibly alters ATII cell cytokine secretion. It is therefore possible that volatile anesthesia, by modulating pulmonary epithelial cell secretion of inflammatory cytokines, might affect lung inflammatory response.
Back to Top | Article Outline


1. Mason RJ, Dobbs LG, Greenleaf RD, Williams MC: Alveolar type II cells. Fed Proc 1977; 36: 2697–702

2. Crestani B, Cornillet P, Dehoux M, Rolland C, Guenounou M, Aubier M: Alveolar type II epithelial cells produce interleukin-6 in vitro and in vivo: Regulation by alveolar macrophage secretory products. J Clin Invest 1994; 94: 731–40

3. Witherden IR, Goldstraw P, Pastorino U, Ratcliffe C, Tetley TD: Chemokine release by primary human alveolar type II cells in vitro. Am J Respir Crit Care Med 1997; 155: A752

4. Crippen TL, Klasing KC, Hyde DM: Cytokine-induced neutrophil chemoattractant production by primary rat alveolar type II cells. Inflammation 1995; 19: 575–86

5. Paine Rd, Rolfe MW, Standiford TJ, Burdick MD, Rollins BJ, Strieter RM: MCP-1 expression by rat type II alveolar epithelial cells in primary culture. J Immunol 1993; 150: 4561–70

6. McRitchie DI, Isowa N, Edelson JD, Xavier AM, Cai L, Man HY, Wang YT, Keshavjee SH, Slutsky AS, Liu M: Production of tumour necrosis factor alpha by primary cultured rat alveolar epithelial cells. Cytokine 2000; 12: 644–54

7. Xavier AM, Isowa N, Cai L, Dziak E, Opas M, McRitchie DI, Slutsky AS, Keshavjee SH, Liu M: Tumor necrosis factor-alpha mediates lipopolysaccharide-induced macrophage inflammatory protein-2 release from alveolar epithelial cells: Autoregulation in host defense. Am J Respir Cell Mol Biol 1999; 21: 510–20

8. Pechkovsky DV, Zissel G, Ziegenhagen MW, Einhaus M, Taube C, Rabe KF, Magnussen H, Papadopoulos T, Schlaak M, Muller-Quernheim J: Effect of proinflammatory cytokines on interleukin-8 mRNA expression and protein production by isolated human alveolar epithelial cells type II in primary culture. Eur Cytokine Netw 2000; 11: 618–25

9. Koyama S, Sato E, Nomura H, Kubo K, Miura M, Yamashita T, Nagai S, Izumi T: Monocyte chemotactic factors released from type II pneumocyte-like cells in response to TNF-alpha and IL-1alpha. Eur Respir J 1999; 13: 820–8

10. Crestani B, Aubier M: Inflammatory role of alveolar epithelial cells. Kidney Int Suppl 1998; 65: S88–93

11. Fink BR, Kenny GE: Metabolic effects of volatile anesthetics in cell culture. A nesthesiology 1968; 29: 505–16

12. McBride WT, Armstrong MA, McBride SJ: Immunomodulation: An important concept in modern anaesthesia. Anaesthesia 1996; 51: 465–73

13. Rannels DE, Roake GM, Watkins CA: Additive effects of pentobarbital and halothane to inhibit synthesis of lung proteins. A nesthesiology 1982; 57: 87–93

14. Rannels DE, Christopherson R, Watkins CA: Reversible inhibition of protein synthesis in lung by halothane. Biochem J 1983; 210: 379–87

15. Wartell SA, Christopherson R, Watkins CA, Rannels DE: Inhibition of synthesis of lung proteins by halothane. Mol Pharmacol 1981; 19: 520–4

16. Welch WD: Halothane reversibly inhibits human neutrophil bacterial killing. A nesthesiology 1981; 55: 650–4

17. Nakagawara M, Takeshige K, Takamatsu J, Takahashi S, Yoshitake J, Minakami S: Inhibition of superoxide production and Ca2+ mobilization in human neutrophils by halothane, enflurane, and isoflurane. A nesthesiology 1986; 64: 4–12

18. Frohlich D, Rothe G, Schwall B, Schmid P, Schmitz G, Taeger K, Hobbhahn J: Effects of volatile anaesthetics on human neutrophil oxidative response to the bacterial peptide FMLP. Br J Anaesth 1997; 78: 718–23

19. Mitsuhata H, Shimizu R, Yokoyama MM: Suppressive effects of volatile anesthetics on cytokine release in human peripheral blood mononuclear cells. Int J Immunopharmacol 1995; 17: 529–34

20. Molliex S, Crestani B, Dureuil B, Bastin J, Rolland C, Aubier M, Desmonts JM: Effects of halothane on surfactant biosynthesis by rat alveolar type II cells in primary culture. A nesthesiology 1994; 81: 668–76

21. Paugam-Burtz C, Molliex S, Lardeux B, Rolland C, Aubier M, Desmonts JM, Crestani B: Differential effects of halothane and thiopental on surfactant protein C messenger RNA in vivo and in vitro in rats. A nesthesiology 2000; 93: 805–10

22. Molliex S, Dureuil B, Aubier M, Friedlander G, Desmonts JM, Clerici C: Halothane decreases Na,K-ATPase, and Na channel activity in alveolar type II cells. A nesthesiology 1998; 88: 1606–13

23. Giraud O, Seince PF, Rolland C, Lecon-Malas V, Desmonts JM, Aubier M, Dehoux M: Halothane reduces the early lipopolysaccharide-induced lung inflammation in mechanically ventilated rats. Am J Respir Crit Care Med 2000; 162: 2278–86

24. Dobbs LG: Isolation and culture of alveolar type II cells. Am J Physiol 1990; 258: L134–47

25. Mason RJ, Williams MC, Greenleaf RD, Clements JA: Isolation and properties of type II alveolar cells from rat lung. Am Rev Respir Dis 1977; 115: 1015–26

26. Mazze RI, Rice SA, Baden JM: Halothane, isoflurane, and enflurane MAC in pregnant and nonpregnant female and male mice and rats. A nesthesiology 1985; 62: 339–41

27. Watanabe N, Kamei S, Ohkubo A, Yamanaka M, Ohsawa S, Makino K, Tokuda K: Urinary protein as measured with a pyrogallol red-molybdate complex, manually and in a Hitachi 726 automated analyzer. Clin Chem 1986; 32: 1551–4

28. Aarden LA, De Groot ER, Schaap OL, Lansdorp PM: Production of hybridoma growth factor by human monocytes. Eur J Immunol 1987; 17: 1411–6

29. Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55–63

30. Rice WR, Whitsett JA: Inhibition of surfactant release from isolated type II cells by compound 48/80. Biochim Biophys Acta 1984; 805: 261–7

31. Kotani N, Takahashi S, Sessler DI, Hashiba E, Kubota T, Hashimoto H, Matsuki A: Volatile anesthetics augment expression of proinflammatory cytokines in rat alveolar macrophages during mechanical ventilation. A nesthesiology 1999; 91: 187–97

32. Takata M, Abe J, Tanaka H, Kitano Y, Doi S, Kohsaka T, Miyasaka K: Intraalveolar expression of tumor necrosis factor-alpha gene during conventional and high-frequency ventilation. Am J Respir Crit Care Med 1997; 156: 272–9

33. Bruce DL: Halothane inhibition of rna and protein synthesis of PHA-treated human lymphocytes. A nesthesiology 1975; 42: 11–4

34. Tschaikowsky K, Ritter J, Schroppel K, Kuhn M: Volatile anesthetics differentially affect immunostimulated expression of inducible nitric oxide synthase: role of intracellular calcium. A nesthesiology 2000; 92: 1093–102

35. Park YC, Jun CD, Kang HS, Kim HD, Kim HM, Chung HT: Role of intracellular calcium as a priming signal for the induction of nitric oxide synthesis in murine peritoneal macrophages. Immunology 1996; 87: 296–302

36. Pajewski TN, Miao N, Lynch C3rd, Johns RA: Volatile anesthetics affect calcium mobilization in bovine endothelial cells. A nesthesiology 1996; 85: 1147–56

Cited By:

This article has been cited 25 time(s).

Artificial Organs
Continuous Monitoring of Inflammation Biomarkers During Simulated Cardiopulmonary Bypass Using a Microfluidic Immunoassay DeviceA Pilot Study
Sasso, LA; Aran, K; Guan, YL; Undar, A; Zahn, JD
Artificial Organs, 37(1): E9-E17.
Acta Anaesthesiologica Scandinavica
Systemic inflammation in the brain-dead organ donor
Barklin, A
Acta Anaesthesiologica Scandinavica, 53(4): 425-435.
International Journal of Molecular Medicine
Desflurane differentially affects the release of proinflammatory cytokines in plasma and bronchoalveolar fluid of endotoxemic rats
Boost, KA; Hofstetter, C; Flondor, M; Betz, C; Homann, M; Pfeilschifrer, J; Muehl, H; Zwissler, B
International Journal of Molecular Medicine, 17(6): 1139-1144.

Acta Anaesthesiologica Scandinavica
Gene expression of pulmonary cytokines after sevoflurane or thiopentone anaesthesia in pigs
Takala, RSK; Soukka, H; Salo, MS; Kirvela, O; Kaapa, P; Aantaa, R
Acta Anaesthesiologica Scandinavica, 50(2): 163-167.
Prostate Cancer and Prostatic Diseases
Persistently high levels of immunosuppressive cytokines in patients after radical prostatectomy
Quatan, N; Meyer, B; Bailey, M; Pandha, H
Prostate Cancer and Prostatic Diseases, 9(4): 420-425.
American Journal of Physiology-Renal Physiology
Isoflurane protects against renal ischemia and reperfusion injury and modulates leukocyte infiltration in mice
Lee, HT; Kim, M; Kim, M; Kim, N; Billings, FT; D'Agati, VD; Emala, CW
American Journal of Physiology-Renal Physiology, 293(3): F713-F722.
Experimental Lung Research
Direct interactions between nitrous oxide and exogenous pulmonary surfactant in vitro
Sosnowski, TR; Gradon, L; Marraro, GA
Experimental Lung Research, 30(4): 311-318.
International Journal of Molecular Medicine
Sevoflurane and isoflurane decrease TNF-alpha-induced gene expression in human monocytic THP-1 cells: Potential role of intracellular I kappa B alpha regulation
Boost, KA; Leipold, T; Scheiermann, P; Hoegl, S; Sadik, CD; Hofstetter, C; Zwissler, B
International Journal of Molecular Medicine, 23(5): 665-671.
European Respiratory Journal
Postconditioning with a volatile anaesthetic in alveolar epithelial cells in vitro
Yue, T; Z'graggen, BR; Blumenthal, S; Neff, SB; Reyes, L; Booy, C; Steurer, M; Spahn, DR; Neff, TA; Schmid, ER; Beck-Schimmer, B
European Respiratory Journal, 31(1): 118-125.
Acta Anaesthesiologica Scandinavica
Effects of sevoflurane and desflurane on cytokine response during tympanoplasty surgery
Koksal, GM; Sayilgan, C; Gungor, G; Oz, H; Sen, O; Uzun, H; Aydin, S
Acta Anaesthesiologica Scandinavica, 49(6): 835-839.
British Journal of Anaesthesia
Effects of propofol and desflurane anaesthesia on the alveolar inflammatory response to one-lung ventilation
Schilling, T; Kozian, A; Kretzschmar, M; Huth, C; Welte, T; Buhling, F; Hedenstierna, G; Hachenberg, T
British Journal of Anaesthesia, 99(3): 368-375.
Anesthesia and Analgesia
Cardioprotection with volatile anesthetics: Mechanisms and clinical implications
De Hert, SG; Turani, F; Mathur, S; Stowe, DF
Anesthesia and Analgesia, 100(6): 1584-1593.
Acta Anaesthesiologica Scandinavica
Isoflurane attenuates pulmonary interleukin-1 beta and systemic tumor necrosis factor-alpha following mechanical ventilation in healthy mice
Vaneker, M; Santosa, JP; Heunks, LM; Halbertsma, FJ; Snijdelaar, DG; van Egmond, J; van den Brink, IA; van de Pol, FM; van der Hoeven, JG; Scheffer, GJ
Acta Anaesthesiologica Scandinavica, 53(6): 742-748.
Anesthesia and Analgesia
The immunomodulatory effect of sevoflurane in endotoxin-injured alveolar epithelial cells
Suter, D; Spahn, DR; Blumenthal, S; Reyes, L; Booy, C; Z'graggen, BR; Beck-Schimmer, B
Anesthesia and Analgesia, 104(3): 638-645.
European Surgical Research
Isoflurane inhalation after induction of endotoxemia in rats attenuates the systemic cytokine response
Flondor, M; Hofstetter, C; Boost, KA; Betz, C; Homann, M; Zwissler, B
European Surgical Research, 40(1): 1-6.
Life Sciences
Effects of inhalation anesthetics halothane, sevoflurane, and isoflurane on human cell lines
Kvolik, S; Glavas-Obrovac, L; Bares, V; Karner, I
Life Sciences, 77(): 2369-2383.
Annales Francaises D Anesthesie Et De Reanimation
Sedation an acute respiratory distress syndrome
Boyadjiev, I; Albanese, J
Annales Francaises D Anesthesie Et De Reanimation, 27(): 604-610.
Halothane Does Not Inhibit the Functional Coupling between the β2-Adrenergic Receptor and the Gαs Heterotrimeric G Protein
Hayashi, M; Penheiter, SG; Nakayama, T; Penheiter, AR; Warner, DO; Jones, KA
Anesthesiology, 104(4): 754-762.

PDF (411)
Protective Effects of Isoflurane Pretreatment in Endotoxin-induced Lung Injury
Reutershan, J; Chang, D; Hayes, JK; Ley, K
Anesthesiology, 104(3): 511-517.

PDF (984)
Anesthetic-induced Improvement of the Inflammatory Response to One-lung Ventilation
De Conno, E; Steurer, MP; Wittlinger, M; Zalunardo, MP; Weder, W; Schneiter, D; Schimmer, RC; Klaghofer, R; Neff, TA; Schmid, ER; Spahn, DR; Z’graggen, BR; Urner, M; Beck-Schimmer, B
Anesthesiology, 110(6): 1316-1326.
PDF (1141) | CrossRef
European Journal of Gastroenterology & Hepatology
Fatal subacute liver failure after repeated administration of sevoflurane anaesthesia
Žižek, D; Ribnikar, M; Žižek, B; Ferlan-Marolt, V
European Journal of Gastroenterology & Hepatology, 22(1): 112-115.
PDF (236) | CrossRef
Sevoflurane Inhibits Phorbol-Myristate-Acetate-induced Activator Protein-1 Activation in Human T Lymphocytes in Vitro: Potential Role of the p38-Stress Kinase Pathway
Loop, T; Scheiermann, P; Doviakue, D; Musshoff, F; Humar, M; Roesslein, M; Hoetzel, A; Schmidt, R; Madea, B; Geiger, KK; Pahl, HL; Pannen, BH
Anesthesiology, 101(3): 710-721.

PDF (1128)
European Journal of Anaesthesiology (EJA)
Study of the systemic and pulmonary oxidative stress status during exposure to propofol and sevoflurane anaesthesia during thoracic surgery: Retracted
Abou-Elenain, K
European Journal of Anaesthesiology (EJA), 27(6): 566-571.
PDF (923) | CrossRef
The Alveolar Epithelium: Suspect or Innocent Bystander?
Gropper, MA; Wiener-Kronish, J
Anesthesiology, 98(1): 3-4.

Mechanical Ventilation in Healthy Mice Induces Reversible Pulmonary and Systemic Cytokine Elevation with Preserved Alveolar Integrity: An In Vivo Model Using Clinical Relevant Ventilation Settings
Snijdelaar, DG; Joosten, LA; van der Hoeven, JG; Scheffer, GJ; Vaneker, M; Halbertsma, FJ; van Egmond, J; Netea, MG; Dijkman, HB
Anesthesiology, 107(3): 419-426.
PDF (1604) | CrossRef
Back to Top | Article Outline

© 2003 American Society of Anesthesiologists, Inc.

Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.

Article Tools